Table I. Patient characteristics and univariate analysis.
*The 3-year overall survival rate is 56.2%. OS: Overall survival; ECOG: Eastern Cooperative Oncology Group; BED: biologically effective dose; LMR: lymphocyte-to-monocyte ratio; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio